Drugs / ML-007C-MA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07459647 | Mar 2026 → Feb 2030 expected | schizophrenia | MapLight Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07459660 | Mar 2026 → Mar 2029 expected | psychotic disorder | MapLight Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT06887192 | Aug 2025 → Dec 2027 expected | psychotic disorder | MapLight Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT07038876 | Jun 2025 → Jun 2026 | schizophrenia | MapLight Therapeutics | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | MapLight Therapeutics | Results MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia maplightrx.com ↗
today announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), in adults with an acute exacerbation of schizophrenia. |
| 2026-01-05 | MapLight Therapeutics | Regulatory MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis maplightrx.com ↗
MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 /M 4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | MapLight Therapeutics | MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia maplightrx.com ↗ |
| 2026-01-05 | MapLight Therapeutics | MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis maplightrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ML-007C-MA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07459647 ↗ |
| Route | Oral | “orally administered ML-007C-MA” NCT07038876 ↗ |